Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiol TherapeuticsSTU:CT9 -2.06%37 EV-to-EBIT is -7.41 as of Aug. 18, 2026. GuruFocus rates STU:CT9 with a GF Score™ of 37/100. The stock has 4 warning signs investors should review. Among 683 Drug Manufacturers companies, Cardiol Therapeutics ranks worse than 146412.74% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cardiol Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was €88.83 Mil.
Cardiol Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-22.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics EV-to-EBIT Related Terms
Cardiol Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's EV-to-EBIT falls into.
Cardiol Therapeutics's current Enterprise Value is €165.00 Mil.
Cardiol Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-22.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics (STU:CT9) has a EV-to-EBIT of -7.41 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardiol Therapeutics and its competitors. According to the industry distribution chart, Cardiol Therapeutics ranks #999999 out of 683 companies in the Drug Manufacturers industry.
Is Cardiol Therapeutics' EV-to-EBIT too high?
Cardiol Therapeutics' current EV-to-EBIT is -7.41. Based on the distribution chart, Cardiol Therapeutics ranks #999999 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #999999 out of 683 companies for EV-to-EBIT. This places Cardiol Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.97, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current EV-to-EBIT is -7.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current EV-to-EBIT of -7.41. The current EV-to-EBIT is -7.41. Cardiol Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current EV-to-EBIT is -7.41 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
37GF Score
Get the complete analysis for STU:CT9
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CT9 has been successfully added to your 
